John Gill - 06 Apr 2026 Form 4 Insider Report for Altimmune, Inc. (ALT)

Reporting relationship: Director
Issuer ticker: ALT
Reported as of: 06 Apr 2026
Net transaction value: +$31,350
SEC form: 4
Accepted by SEC: 06 Apr 2026, 16:05:16 UTC
Prior SEC filing: 23 Dec 2025
Next SEC filing: 01 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Gregory Weaver, as Attorney-in-Fact

Key filing fact

John Gill filed Form 4 for Altimmune, Inc. (ALT) on 06 Apr 2026.

Key facts

This page summarizes John Gill's Form 4 filing for Altimmune, Inc. (ALT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 06 Apr 2026, 16:05.

Change

Previous filing in this sequence was filed on 23 Dec 2025.
Current net transaction value: +$31,350.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001409939 Primary reporting owner

GILL JOHN

Relationship: Director
Address: 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG
Signature: /s/ Gregory Weaver, as Attorney-in-Fact
Signature date: 06 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALT transaction

Common Stock, par value $0.0001

Purchase

Transaction value: $31,350
Shares: +9,200
Change %: +74%
Price: $3.41
Shares after: 21,700
Date: 06 Apr 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.4050 to $3.4080, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.